Mexico Home Infusion Therapy Market

Mexico Home Infusion Therapy Market Executive Summary

The Mexico Home Infusion Therapy market is at around $539.4 Mn in 2023 and is projected to reach $945.6 Mn in 2030, exhibiting a CAGR of 8.35% during the forecast period.

Medical treatment at hospitals and clinics for patients suffering from chronic diseases is not only expensive in the long run, but also inconvenient and cumbersome which ultimately leads to reduced quality of life. As a result, home infusion therapy has evolved as a comprehensive medical treatment which provides an alternative to the in-patient healthcare which is both affordable and convenient for the patients. Home infusion therapy refers to the administration of medications through a needle or catheter to patients at a place other than hospitals and clinics, usually their homes. Home infusion is frequently advised when oral medications are ineffective and when there is a strong need for parenteral administration of drugs. “Infusion therapy” usually refers to the intravenous administration of a medicine, but it can also describe circumstances in which alternative non-oral drug delivery methods, such as intramuscular injections and epidural routes, are used. Prescription drug therapies commonly administered via infusion therapy include antibiotic, antifungal, antiviral, chemotherapy, hydration, pain management and parenteral nutrition. Specialty infusion therapies can also be used to treat autoimmune deficiencies, multiple sclerosis, rheumatoid arthritis, cancer, congestive heart failure, haemophilia, and other disorders. A home infusion therapy provider is state-licensed pharmacy that is specialized in providing such treatment to patients in their homes or other alternative sites. An infusion therapy is only initiated upon the permission of a licensed physician who is supervising the patient’s care. To ensure safety and efficacy of the treatment, various services are performed by the healthcare givers include, but are not limited to, patient assessment and education, maintenance of appropriate documentation, adverse effect and drug interaction monitoring, and lastly, quality control of all the infusion medication and equipment.

Chronic diseases are a significant healthcare burden in Mexico, contributing to high morbidity and mortality rates and placing considerable pressure on the healthcare system. The Mexico Home Infusion Therapy Market is driven by significant factors such as the rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. However, uncertain reimbursement policies, limited availability of nurses, and infrastructure and accessibility issues restrict the growth and potential of the market.

The major players of the Mexico Home Infusion Therapy Market are Option Care Health, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others. Fresenius Kabi manufactures and distributes a wide range of products used in infusion therapy, including IV solutions and medications, infusion pumps and related devices, catheters and administration set, and nutritional products for parenteral nutrition

Market Dynamics

Market Growth Drivers

Rising Prevalence of Chronic Diseases: Mexico’s epidemiologic transition towards chronic diseases is significantly affecting its society as a whole and the health system in particular. Home infusion is a safe and effective method to manage these chronic conditions as it is convenient which leads to improved patient adherence and treatment outcomes. For example, chemotherapy medications can be safely given to cancer patients at home, which lowers hospital stays and enhances patient comfort while receiving treatment. For patients with extensive diabetes care needs, insulin or other drugs can also be administered at home by infusion. Consequently, there is an increasing need for novel and efficient treatment approaches due to the increased prevalence of chronic illnesses. Because of its affordability, flexibility to different chronic conditions, and ease of use, home infusion therapy is becoming more and more popular as a means of managing chronic illnesses and enhancing patient quality of life, which is driving the market’s overall expansion.

Expanding Geriatric Population:  A key feature of demographic trends in Mexico is the rapid rate at which the older population is growing. According to the data from Statista, in 2022, the age group 65 and older constituted 8.32% of the total population. As people age, they get more prone to long-term illnesses including diabetes, heart failure, and autoimmune disorders as they age. Many times, these illnesses necessitate long-term care using drugs that may be efficiently administered at home via infusion therapy. Moreover, the aging population is marked by a decline in mobility, which makes regular hospital visits difficult. A practical substitute is home infusion therapy, which enables patients to receive treatment in the comfort of their own homes, enhancing their quality of life and lessening the strain on caregivers. Furthermore, hospital environments can raise the risk of infection for older persons, who are more vulnerable to illnesses. However, home infusion therapy can improve patient outcomes by lowering the chance of contracting infections acquired outside of a hospital. The market for home infusion therapy is ultimately driven by the number of potential patients who may need it to manage chronic diseases, which is generally increased with the aging population.

Technological advancements: The home infusion therapy market is expected to grow at a high rate due to the numerous advantages that technological advancements provide. Patients can move around more freely and independently while receiving therapy because of the smaller, lighter, and more user-friendly designs of more recent portable pump models. In order to improve safety and convenience, real-time data transfer from infusion pumps to healthcare providers allows for remote monitoring of medicine distribution and patient vitals. Automated dose calculations, preprogrammed reminders, and malfunction alarms are just a few of the features that smart infusion pumps provide to increase medication accuracy and lower error rates. These technical developments result in better patient acceptance, a wider range of treatments, greater efficiency for medical professionals, and lower costs, all of which raise demand and fuel the market for home infusion therapy.

Market Restraints

Uncertain Reimbursement Policies: The varied and unclear reimbursement policies from private insurance companies and the government can limit patient access to home infusion therapy. Even though, home infusion therapy is much more affordable to patients rather than receiving in-patient care, there can be high costs associated with certain speciality infusion therapies. These high costs associated with specialty infusion treatment may discourage patients, especially those without adequate insurance coverage. Due to this, the Home Infusion Therapy Market gets affected as it faces resistance from the patients.

Limited Availability of Nurses: One of the major challenges of home infusion therapy is the shortage of trained nurses which results in fewer people being able to receive care at home and lengthier wait times. Prolonged wait times eventually prevents patients from using home infusion therapy and choose an alternative treatment. To attract and retain qualified healthcare professions, providers of home infusion therapy may need to offer higher salaries. This increases the operating expenses, which leads to overall high cost of the treatment, further restricting the market access. Thus, the market for home infusion therapy is constrained by a lack of competent workers which ultimately slows the market growth.

Infrastructure and Accessibility Issues: In isolated or rural places, the availability of home infusion therapy services may be restricted. Patients who do not have access to qualified clinicians and necessary equipment for the home infusion therapy suffer. Additionally, the growth of home infusion therapy in some areas may not have sufficient cold chain logistics for the storage and transportation of temperature-sensitive drugs. As a result, this impacts the expansion of the home infusion therapy market as a whole.

Regulatory Landscape and Reimbursement Scenario

In Mexico, the Federal Commission for Protection against Health Risks (COFEPRIS or Comisión Federal para la Protección contra Riesgos Sanitarios) is a regulatory body of the Mexican Government; a decentralized organ of the Mexican Secretariat of Health. Among the many health-related issues it regulates in Mexico are pharmaceuticals, food safety, medical devices, organ transplants, and environmental preservation. COFEPRIS is in charge of the entire drug approval process, from the initial application to the post-market surveillance (PMS) stage, including supply and demand, advertising, commercialization, imports and exports, distribution, manufacturing, and supply.

Mexico’s pharmaceutical industry is thriving and expanding, and thus strict laws are in place to guarantee the security and effectiveness of medications made available to Mexican residents. Pharmaceutical companies seeking to sell their medications in Mexico must understand the procedure thoroughly for getting approval. The overall approval includes an extensive evaluation by COFEPRIS, accompanied by facility inspection to ensure GMP compliance. There are three different pathways for registering medicinal product with COFEPRIS. The New Drug Registration is the pathway applicable for new chemical entities that have not previously marketed anywhere in the world. Next, is the Generic Drug Registration for drugs that are similar to the already-marketed reference drugs. Lasty, Biosimilar Registration is applicable to the biological products that are similar to the approved reference biological product.

The healthcare reimbursement system in Mexico is characterized by a complex interplay between public and private sectors. For the public sector, the social security institutions are the main provider of public health insurance. Workers in the formal sector and their dependents are covered by the Instituto Mexicano del Seguro Social (IMSS). Government employees and their families are covered by the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE). To supplement public plans with extra coverage, many Mexicans opt to buy private health insurance which provides access to a greater variety of healthcare providers, such as private hospitals and specialists. The healthcare reimbursement scheme in Mexico is gradually evolving. Although many people have a safety net in public services, there are still large differences. In the future, there may be initiatives to increase public-private partnership, achieve universal coverage, and use technology to improve healthcare affordability and accessibility for all.

Competitive Landscape

Key Players

Here are some of the major key players in the Mexico Home Infusion Therapy Market:

• Option Care Health
• Baxter International
• ICU Medical (Smiths Medical)
• Becton, Dickinson and Company (BD)
• Fresenius Kabi
• Medtronic
• IVX Health
• B. Braun Melsungen AG
• Terumo Corporation
• CareFusion Corporation